Endpoints News· @endpts · X·· 3 小时前精选AI 评分72
AI 导读
辉瑞将向中国生物技术公司Starna Therapeutics支付3.3亿美元首付款,以获得其体内CAR-T资产,此举标志着辉瑞进入该领域。交易细节见Endpoints News报道。
推荐理由
辉瑞以3.3亿美元首付款引进体内CAR-T资产,读者可据此观察跨国药企在这一技术方向的布局动作。
正文
Pfizer will pay $330M upfront to Chinese biotech Starna Therapeutics for in vivo CAR-T assets, marking its entry into the space. https://endpoints.news/pfizer-gets-into-in-vivo-car-t-through-licensing-deal-with-starna-therapeutics/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com